# Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

> **NCT03741127** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Poseida Therapeutics, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Rimiducid may be administered as indicated

## Key facts

- **NCT ID:** NCT03741127
- **Lead sponsor:** Poseida Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-29
- **Primary completion:** 2032-08
- **Final completion:** 2032-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03741127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03741127, "Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03741127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*